A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2575 | 2011 |
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2458 | 2016 |
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 1924 | 2016 |
Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1779 | 2019 |
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... Journal of clinical oncology 32 (13), 1302-1308, 2014 | 1706 | 2014 |
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ... International Journal of Gynecologic Cancer 31 (1), 2021 | 1459 | 2021 |
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... Annals of oncology 30 (5), 672-705, 2019 | 1114 | 2019 |
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 911 | 2015 |
Cancer of the corpus uteri F Amant, MR Mirza, M Koskas, CL Creutzberg International Journal of Gynecology & Obstetrics 143, 37-50, 2018 | 413 | 2018 |
Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 385 | 2014 |
ESMO-ESGO-ESTRO endometrial consensus conference working group N Colombo, C Creutzberg, F Amant, T Bosse, A Gonzalez-Martin, ... ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis …, 2016 | 311 | 2016 |
Dostarlimab for primary advanced or recurrent endometrial cancer MR Mirza, DM Chase, BM Slomovitz, R dePont Christensen, Z Novák, ... New England Journal of Medicine 388 (23), 2145-2158, 2023 | 275 | 2023 |
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the … J Pfisterer, B Weber, A Reuss, R Kimmig, A Du Bois, U Wagner, ... Journal of the National Cancer Institute 98 (15), 1036-1045, 2006 | 262 | 2006 |
The forefront of ovarian cancer therapy: update on PARP inhibitors MR Mirza, RL Coleman, A González-Martín, KN Moore, N Colombo, ... Annals of Oncology 31 (9), 1148-1159, 2020 | 260 | 2020 |
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 254 | 2021 |
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ... Annals of oncology 33 (9), 860-877, 2022 | 250 | 2022 |
Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ... Annals of Oncology 28 (4), 727-732, 2017 | 246 | 2017 |
AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... J Clin Oncol 30, 327s, 2012 | 238 | 2012 |
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup … A du Bois, B Weber, J Rochon, W Meier, A Goupil, S Olbricht, JC Barats, ... Journal of clinical oncology 24 (7), 1127-1135, 2006 | 234 | 2006 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial A Du Bois, G Kristensen, I Ray-Coquard, A Reuss, S Pignata, N Colombo, ... The Lancet Oncology 17 (1), 78-89, 2016 | 233 | 2016 |